Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia

Phase 2 clinical trial to evaluate the combination of venetoclax, cytarabine and metformin in relapsed-refractory and induction ineligible acute myeloid leukemia.

Trial Details

NCT ID
NCT06537843
Phase
PHASE2
Sponsor
Hospital Municipal São José
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Venetoclax
  • Cytarabine Injection
  • Metformin
Locations (sample)
  • Belém, Brazil|-1.45583,-48.50444
  • Curitiba, Brazil|-25.42778,-49.27306
  • Florianópolis, Brazil|-27.59667,-48.54917
  • Jaú, Brazil|-22.29639,-48.55778
  • Joinville, Brazil|-26.30444,-48.84556

Key Eligibility Criteria

  • Diagnosis of AML in accordance with the World Health Organization criteria.
  • Ineligibility for induction chemotherapy due to age (≥ 70 years) or, for patients 18 to 74 years of age, ECOG-PS 2 or 3, creatinine clearance below…
  • Projected life expectancy of at least 12 weeks.
  • Not requiring supplemental oxygen or substitutive renal therapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →